Skip to Content
Find More Like This
Return to Search

Anti-cancer agents based on 4-(hetero)Ary1-1,2,5-oxadiazol-3-yl Amino derivatives and a method of making

United States Patent

January 29, 2013
View the Complete Patent at the US Patent & Trademark Office
U.S. Department of Energy - Visit the Office of the Assistant General Counsel for Technology Transfer & Intellectual Property Website
The present disclosure relates to novel compounds that can be used as anti-cancer agents in the prostate cancer therapy. ##STR00001## In particular, the invention relates N-substituted derivatives of 4-(hetero)aryl-1,2,5-oxadiazol-3-yl amines having the structural Formula (I) and (II), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or pharmaceutically acceptable salt and/or solvate thereof. Meaning of R1 and R2 in the Formula (I) and (II) are defined in claim 1. The invention also relates to methods for preparing said compounds, and to pharmaceutical compositions comprising said compounds.
Gakh; Andrei A. (Bethesda, MD), Krasavin; Mikhail (Moscow Region, RU), Karapetian; Ruben (Moscow, RU), Rufanov; Konstantin A. (Moscow, RU), Konstantinov; Igor (Moscow, RU), Godovykh; Elena (Rostov-na-Donu, RU), Soldatkina; Olga (Moscow, RU), Sosnov; Andrey V. (Moscow, RU)
U.S. Department of Energy (Washington, DC)
12/ 822,243
June 24, 2010
CONTRACTUAL ORIGIN OF THE INVENTION The U.S. Government has certain rights in the present invention pursuant to Contract No. #3548 between the Department of Energy (DOE) (International Science and Technology Center) and the Chemical Diversity Research Institute, dated Jul. 1, 2007.